Abstract
In this observational cohort study, 10 patients with extensive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a. Tumor responses were observed in 9 patients with a median progression-free survival of 645 days. Peginterferon alfa-2a could be an effective therapy for extensive or treatment-resistant Kaposi sarcoma.
Keywords:
HIV/AIDS; Kaposi sarcoma; highly active antiretroviral therapy; peginterferon alfa-2a; treatment effectiveness.
MeSH terms
-
AIDS-Related Opportunistic Infections / drug therapy*
-
AIDS-Related Opportunistic Infections / physiopathology
-
AIDS-Related Opportunistic Infections / virology
-
Adult
-
Anti-Retroviral Agents / therapeutic use
-
Antiretroviral Therapy, Highly Active
-
Cohort Studies
-
Female
-
Humans
-
Interferon-alpha / therapeutic use*
-
Male
-
Middle Aged
-
Polyethylene Glycols / therapeutic use*
-
RNA, Viral / blood
-
Recombinant Proteins / therapeutic use
-
Sarcoma, Kaposi / drug therapy*
-
Sarcoma, Kaposi / physiopathology
-
Sarcoma, Kaposi / virology
-
Treatment Outcome
-
Viral Load
Substances
-
Anti-Retroviral Agents
-
Interferon-alpha
-
RNA, Viral
-
Recombinant Proteins
-
Polyethylene Glycols
-
peginterferon alfa-2a
Supplementary concepts
-
AIDS-related Kaposi sarcoma